Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionEGFR tyrosine kinase inhibitor
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of ActionEpidermal growth factor (EGF) receptor 1 (HER1) (ErbB1) inhibitor
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat advanced EGFR mutation-positive non-small cell lung cancer (NSCLC) with brain metastasis
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today